论文部分内容阅读
目的探讨替莫唑胺联合放疗治疗恶性脑胶质瘤的疗效。方法 68例术后经病理组织学诊断为恶性脑胶质瘤患者随机分为治疗组和对照组。治疗组(32例)放疗后应用替莫唑胺化疗5个疗程,对照组(36例)仅采用放疗。疗程结束后进行随访,观察两组临床有效率、无进展生存时间、总的生存时间及替莫唑胺的不良反应。结果治疗组临床有效率,无进展生存时间、总的生存时间都高于对照组,差异有统计学意义(P<0.05),不良反应轻微。结论替莫唑胺联合放疗治疗恶性脑胶质瘤有效,且不良反应低,具有临床应用价值。
Objective To investigate the efficacy of temozolomide combined with radiotherapy in the treatment of malignant glioma. Methods Sixty-eight patients with pathologically diagnosed malignant gliomas were randomly divided into treatment group and control group. The treatment group (32 cases) received 5 courses of temozolomide after radiotherapy and the control group (36 cases) received radiotherapy alone. Follow-up after the end of treatment, clinical efficacy, progression-free survival, overall survival and temozolomide adverse reactions were observed. Results The clinical effective rate, progression-free survival time and overall survival time in the treatment group were all higher than those in the control group (P <0.05). The adverse reactions were mild. Conclusion Temozolomide combined with radiotherapy for the treatment of malignant glioma is effective and has a low adverse reaction rate. It has clinical value.